EAPI.PA Euroapi SAS

Healthcare Pharmaceuticals Euronext Paris
0.7970 EUR
Close of Nov 7, 2026
0.7130 3.39
Market cap
EUR 76.1M
P/E
-
P/B
0.11x
ROE
-84.7%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is EAPI.PA undervalued?

Graham number

The Graham number of Euroapi SAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Euroapi SAS fundamental analysis

4 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-1.42%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-0.88%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

The stock's low PBV ratio (0.45x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a minimal amount of debt (11%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

Assets Growth 2/2

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Buffet Intrinsic Value 0/1

Based on Warren Buffett's formula, the company's stock seems overpriced (-167), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Euroapi SAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Euroapi SAS

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostag…

Full company profile